Kuzmits R, Ludwig H, Legenstein E, Szekeresz T, Kratzik C, Hofbauer J
J Clin Chem Clin Biochem. 1986 Feb;24(2):119-24. doi: 10.1515/cclm.1986.24.2.119.
Serum and urinary neopterin concentrations were measured in 142 patients suffering from various malignant diseases. Increased serum and urinary neopterin levels were found in 48% and 55% of patients respectively. Neopterin showed sufficient sensitivity in the detection of haematological disorders and hypernephroma, whereas the sensitivity of neopterin was rather poor in patients with other solid tumours. Comparison of serum alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG) concentrations and serum or urinary neopterin levels in testicular cancer patients showed that determination of neopterin provides no further information in the management of these patients. In testicular cancer patients receiving adjuvant chemotherapy, a significant increase in serum (p less than 0.005) and urinary (p less than 0.0005) neopterin concentrations was measured after chemotherapy, reflecting the release of neopterin from macrophages during the damage by cytotoxic drugs. In the adjuvant testicular tumour patients, known to be tumour free, 1 out of 16 patients showed elevated serum and 3 out of 15 patients showed false positive urinary neopterin levels. False positive serum (24%) and urinary (37%) neopterin values were also obtained in 28 patients with various nonmalignant diseases, but no evidence for an inflammatory process. In 23 patients with inflammatory diseases pathological serum and urinary neopterin levels were measured in 55% and 59% respectively. When a RIA was compared with a HPLC method, higher urinary neopterin values were obtained with the RIA, indicating that non-oxidized pterines are also determined by the RIA method. In conclusion, neopterin might be a helpful biological marker in monitoring patients with malignant haematological disorders and renal cell carcinoma, but provides no additional information in other solid tumours studied.
对142例患有各种恶性疾病的患者测定了血清和尿新蝶呤浓度。分别在48%和55%的患者中发现血清和尿新蝶呤水平升高。新蝶呤在血液系统疾病和肾细胞癌的检测中表现出足够的敏感性，而在其他实体瘤患者中，新蝶呤的敏感性相当差。对睾丸癌患者的血清甲胎蛋白（AFP）和人绒毛膜促性腺激素（HCG）浓度以及血清或尿新蝶呤水平进行比较，结果表明，测定新蝶呤对这些患者的治疗管理并无更多帮助。在接受辅助化疗的睾丸癌患者中，化疗后测定的血清（p<0.005）和尿（p<0.0005）新蝶呤浓度显著升高，这反映了细胞毒性药物损伤巨噬细胞时新蝶呤的释放。在已知无肿瘤的辅助性睾丸肿瘤患者中，16例患者中有1例血清升高，15例患者中有3例尿新蝶呤水平呈假阳性。在28例患有各种非恶性疾病但无炎症过程证据的患者中，也获得了血清（24%）和尿（37%）新蝶呤值的假阳性结果。在23例炎症性疾病患者中，分别有55%和59%测定了病理性血清和尿新蝶呤水平。当将放射免疫分析（RIA）与高效液相色谱（HPLC）方法进行比较时，RIA获得的尿新蝶呤值更高，这表明RIA方法也能测定非氧化型蝶呤。总之，新蝶呤可能是监测恶性血液系统疾病和肾细胞癌患者的有用生物学标志物，但对所研究的其他实体瘤并无额外帮助。
